Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Sayala, HA
Moreton, P
Jones, RA
Rawstron, AC
O'Connor, SJ
Evans, P
Carter, A
Dearden, C
Matutes, E
Pettitt, AR
Kennedy, DB
Hillmen, P
机构：
[1] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Inst Canc Res, Haematooncol Dept, London SW3 6JB, England
[4] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [1] Interim report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, H
    Moreton, P
    Richard, JA
    Andy, RC
    Sheila, O
    Paul, E
    Anthony, C
    Claire, D
    Estella, M
    Andrew, PR
    Daniel, KB
    Peter, H
    BLOOD, 2005, 106 (11) : 599A - 600A
  • [2] Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy C.
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 14A - 15A
  • [3] Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire E.
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Barrans, Sharon
    Worrillow, Lisa
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 407 - 408
  • [4] Report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab and fluclarabine in patients with fluclarabine refractory CLL (on behalf of the NCRI CLL trials sub-group)
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A. C.
    O'Connor, S. J.
    Evans, P. E.
    Carter, A.
    Dearden, C.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, B. D.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 3 - 3
  • [5] Long term survival report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory chronic lymphocytic leukaemia
    Varghese, A. M.
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A.
    O'Connor, S. J.
    Evans, P.
    Anthony, C.
    Dearden, C. E.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, D. B.
    Barrans, S.
    Worrillow, L.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 46 - 46
  • [6] NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Cohen, Dena
    Pocock, Christopher F. E.
    Rawstron, Andy
    Gregory, Walter M.
    Smith, Alex
    Skinner, Emma
    Critchley, Anne
    Milligan, Donald
    Dearden, Claire E.
    McCarthy, Helen
    Fegan, Chris
    Follows, George A.
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 33 - 34
  • [7] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Ritgen, Matthias
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 1087 - 1087
  • [8] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
  • [9] NCRN CLL207 study of alemtuzumab consolidation in chronic lymphocytic leukaemia: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group)
    Varghese, A. M.
    Cohen, D.
    Pocock, C. F. E.
    Rawstron, A.
    Gregory, W. M.
    Smith, A.
    Skinner, E.
    Critchley, A.
    Milligan, D.
    Dearden, C. E.
    McCarthy, H.
    Fegan, C.
    Follows, G. A.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 8 - 8
  • [10] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL study group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
12345